The drug Bosulif is a form of bosutinib, which is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1]. The patents that cover the product Bosulif are held by Pfizer, Inc.

According to DrugPatentWatch.com, Pfizer, Inc. holds several patents for bosutinib, the active ingredient in Bosulif [2]. The first patent, US9243052B2, is set to expire in December 2029 [2]. This patent covers the method of treating CML and Ph+ ALL with bosutinib [2]. Another patent, US9630559B2, is set to expire in May 2031 and covers the method of treating CML and Ph+ ALL with bosutinib in combination with other drugs [2].

It is worth noting that these patents cover the method of treatment, not the drug itself. The drug bosutinib was approved by the FDA in 2012, and generic versions of bosutinib may become available before these patents expire [3].

In summary, Pfizer, Inc. holds several patents for the method of treatment of CML and Ph+ ALL with bosutinib, the active ingredient in Bosulif. These patents are set to expire in December 2029 and May 2031.

Sources:

1. Bosulif (bosutinib) tablets, for oral use. Pfizer. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203056s000lbl.pdf>
2. DrugPatentWatch.com. Pfizer, Inc. Bosutinib. <https://www.drugpatentwatch.com/drugs/bosutinib>
3. FDA approves new treatment for chronic myelogenous leukemia. FDA. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-chronic-myelogenous-leukemia>